| 魏景健,牛倩倩,张爱侠,等.卡瑞利珠单抗和化疗联合阿帕替尼救治性治疗复发或晚期头颈鳞癌的疗效分析[J].安徽医药,2025,29(1):174-177. |
| 卡瑞利珠单抗和化疗联合阿帕替尼救治性治疗复发或晚期头颈鳞癌的疗效分析 |
| Efficacy of camrelizumab and chemotherapy plus apatinib in recurrent or advanced head and neck squamous cell carcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2025.01.036 |
| 中文关键词: 头颈部肿瘤 癌，鳞状细胞 卡瑞利珠单抗 阿帕替尼 免疫治疗 化疗 |
| 英文关键词: Head and neck tumor Carcinoma,squamous cell Camrelizumab Apatinib Immunotherapy Chemotherapy |
| 基金项目:国家口腔疾病临床医学研究中心开放课题项目( NCRCO-202101)；徐州市科技项目( KC23172) |
|
| 摘要点击次数: 480 |
| 全文下载次数: 213 |
| 中文摘要: |
| 目的观察卡瑞利珠单抗和化疗联合阿帕替尼救治性治疗复发或晚期头颈鳞癌( HNSCC)的疗效及安全性。方法回顾性分析 2020年 3月至 2021年 11月徐州市中心医院口腔科收治的 8例复发或晚期 HNSCC病人，予卡瑞利珠单抗和化疗行 2周期治疗后，待瘤体缩小，卡瑞利珠单抗和阿帕替尼维持性治疗；主要观察指标为疾病控制率( DCR)和客观缓解率( ORR)次要观察指标为总生存期( OS)、无进展生存时间( PFS)和不良反应发生率。结果纳入 8例复发 /晚期 HNSCC病人中， ORR为，62.5%(5/8)，DCR为 87.5%(7/8)。随访时间为 1~32个月，中位 OS为 18个月，中位 PFS未达到，不良反应发生率为 100%，但程度较轻。结论卡瑞利珠单抗和化疗联合阿帕替尼治疗复发或晚期 HNSCC病人具有较好的疗效，能够有效控制疾病进展，提高病人生存质量。 |
| 英文摘要: |
| Objective To observe the efficacy and safety of camrelizumab and chemotherapy plus apatinib in the salvageable treat-ment of recurrent or advanced head and neck squamous cell carcinoma (HNSCC). Methods Eight patients with recurrent or advancedHNSCC admitted to the Department of Stomatology of Xuzhou Central Hospital from March 2020 to November 2021 were retrospective-ly analyzed. After two cycles of treatment with camrelizumab and chemotherapy, camrelizumab and apatinib were used as maintenancetreatment after tumor shrinkage.The main observation indexes were disease control rate (DCR) and objective remission rate (ORR) ,andthe secondary observation indexes were overall survival time (OS),progression free survival time (PFS) and incidence of adverse reac-tions. Results Among 8 patients with recurrent or advanced HNSCC, ORR was 62.5% (5/8) and DCR was 87.5%(7/8).The follow-up time was 1-32 months, the median OS was 18 months, the median PFS was not reached, and the incidence of adverse reactions was100%, but the degree was mild. Conclusion Camrelizumab and chemotherapy plus apatinib has good efficacy in the treatment of re-current or advanced HNSCC patients, which can effectively control disease progression and improve patients' quality of life. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
